Our data demonstrate the preclinical efficacy of TTI-101 in SMARCB1-deficient tumors and suggest that SMARCB1 deficiency may predict response to STAT3 inhibition in metastatic BLCA. This evidence concerns the gene SMARCB1 and bladder transitional cell carcinoma.